An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Corticotropin (Primary)
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- 01 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 01 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
- 15 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017.